BioVie Inc. (BIVI) Financial Ratios
13 years of historical data (2013–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.12
↓-99% vs avg
5yr avg: 12.48
30Y Low0.7·High41.6
ROE
↑
-101.6%
↓+87% vs avg
5yr avg: -803.2%
30Y Low-397%·High-14%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BIVI Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
BioVie Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2M | $14M | $18M | $140M | $36M | $210M | $7M | $3M | $517118 | $3M | $3M |
| Enterprise Value | $-14919500 | $-3528962 | $364362 | $135M | $29M | $206M | $8M | $3M | $1M | $3M | $3M |
| P/E Ratio → | -0.13 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.12 | 0.72 | 1.17 | 9.13 | 9.74 | 41.63 | — | 1.56 | 4.65 | 2.24 | 1.64 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
BIVI EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
BIVI Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -101.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -101.6% | -101.6% | -208.3% | -528.7% | -598.2% | -2579.0% | — | -218.0% | -380.4% | -86.6% | -46.4% |
| ROA | -75.0% | -75.0% | -106.5% | -182.0% | -199.4% | -3203.9% | -716.0% | -102.9% | -106.3% | -52.4% | -28.9% |
| ROIC | — | — | -597.9% | -890.5% | — | — | — | -139.6% | -171.2% | -78.0% | -43.8% |
| ROCE | -102.8% | -102.8% | -176.5% | -246.6% | -259.6% | -2733.6% | — | -162.8% | -177.7% | -85.2% | -46.4% |
BIVI Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $18M exceeds total debt of $349894, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.39 | 0.94 | 3.34 | — | — | — | 7.43 | 0.03 | 0.01 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.90 | -1.14 | -0.33 | -1.74 | -0.89 | — | -0.16 | 7.02 | 0.03 | -0.06 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -54.30 | -54.30 | -11.12 | -10.48 | -12.60 | -246.77 | -0.56 | -9146.52 | -57.91 | — | — |
Net cash position: cash ($18M) exceeds total debt ($349894)
BIVI Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
BioVie Inc.'s current ratio of 9.10x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.35x to 9.10x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.10 | 9.10 | 2.57 | 2.35 | 4.50 | 4.62 | 0.02 | 1.52 | 0.04 | 0.01 | 0.16 |
| Quick Ratio | 9.10 | 9.10 | 2.57 | 2.35 | 4.50 | 4.62 | 0.02 | 1.52 | 0.04 | 0.01 | 0.16 |
| Cash Ratio | 7.71 | 7.71 | 2.55 | 2.34 | 4.47 | 4.53 | 0.00 | 0.77 | 0.04 | 0.01 | 0.15 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
BIVI Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
BioVie Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | 1.5% | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 33.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 34.5% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $1M | $451853 | $324834 | $246625 | $124031 | $49295 | $25396 | $7661 | $7151 | $6976 |
Peer Comparison
Compare BIVI with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BIVIYou | $2M | -0.1 | — | — | — | — | -101.6% | — | — |
 SAVA | $94M | -3.8 | — | — | — | — | -17.2% | -634.1% | — |
 NRXP | $85M | -2.3 | — | — | — | -1324.4% | — | — | — |
 ATHA | $17M | -0.2 | — | — | — | — | -290.8% | — | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 CORT | $5B | 62.3 | 114.9 | 38.7 | 98.3% | 5.9% | 15.0% | 6.2% | 0.1 |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 AVXL | $289M | -5.8 | — | — | — | — | -43.1% | — | — |
 AGIO | $2B | -3.9 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 ALDX | $104M | -1.8 | — | — | — | — | -58.5% | -369.4% | — |
| Healthcare Median | — | 22.3 | 14.5 | 18.5 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 13 years · Updated daily
See BIVI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BIVI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BIVI vs SAVA
Side-by-side business, growth, and profitability comparison vs Cassava Sciences, Inc..
Start ComparisonBIVI — Frequently Asked Questions
Quick answers to the most common questions about buying BIVI stock.
What is BioVie Inc.'s P/E ratio?
BioVie Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
What is BioVie Inc.'s ROE?
BioVie Inc.'s return on equity (ROE) is -101.6%. The historical average is -172.3%.
Is BIVI stock overvalued?
Based on historical data, BioVie Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.